Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer

BACKGROUND: Programmed cell death protein‐1/programmed cell death ligand‐1 (PD‐1/L1) inhibitor is a promising therapeutic option that can be used as either a first‐line or second‐line treatment for driver‐negative advanced or metastatic squamous non‐small cell lung cancers (sqNSCLC). However, reuse...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Rihua, Zhou, Zhen, Liu, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067111/
https://www.ncbi.nlm.nih.gov/pubmed/36373001
http://dx.doi.org/10.1002/cam4.5440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067111/
https://www.ncbi.nlm.nih.gov/pubmed/36373001
http://dx.doi.org/10.1002/cam4.5440

Ejemplares similares